A Finnish nationwide population-based study on the survival of patients with peripheral T-cell lymphoma
Abstract Peripheral T-cell lymphomas (PTCLs) represent a heterogeneous group of rare malignancies with poor survival; however, population-based long-term survival data remain limited. We conducted a nationwide study to estimate overall survival (OS) and relative survival (RS) among 915 patients diag...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2025-07-01
|
| Series: | Scientific Reports |
| Online Access: | https://doi.org/10.1038/s41598-025-12596-1 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849766729991847936 |
|---|---|
| author | Taina Reunamo Ilja Kalashnikov Kreetta Lahtela Marjukka Pollari Leevi Viisanen Susanna Mannisto Sirkku Jyrkkiö Sirpa Leppä |
| author_facet | Taina Reunamo Ilja Kalashnikov Kreetta Lahtela Marjukka Pollari Leevi Viisanen Susanna Mannisto Sirkku Jyrkkiö Sirpa Leppä |
| author_sort | Taina Reunamo |
| collection | DOAJ |
| description | Abstract Peripheral T-cell lymphomas (PTCLs) represent a heterogeneous group of rare malignancies with poor survival; however, population-based long-term survival data remain limited. We conducted a nationwide study to estimate overall survival (OS) and relative survival (RS) among 915 patients diagnosed with PTCLs from 2002 − 2018 (57% males, median age 67 years) using the Finnish Cancer Registry. The most common subtypes included PTCL not otherwise specified (PTCL NOS; 37%), angioimmunoblastic T-cell lymphoma (AITL; 27%), and ALK-anaplastic large cell lymphoma (ALK-ALCL; 12%). Age > 60 years at diagnosis, advanced stage, and male sex were associated with poorer OS. Five-year OS and RS were better in patients with ALK + ALCL compared with PTCL NOS (5-year OS: 85% vs 30%). Patients with ALK- ALCL had a favorable 5-year OS compared to PTCL NOS (46% vs 30%), while those with enteropathy-associated T-cell lymphoma (EATL) demonstrated worse OS (15%). There was no improvement in RS from 2002 − 2012 to 2013 − 2018. OS was better in patients (excluding ALK + ALCL) receiving high-dose chemotherapy (HDCT) compared to those for whom HDCT was not planned (HR 0.61; 95% CI 0.47 − 0.80). We conclude that RS did not improve during the study period; however, consolidation with HDCT for eligible patients resulted in favorable survival. |
| format | Article |
| id | doaj-art-3c6819dcd0e64b31bf33bddfe487ca6f |
| institution | DOAJ |
| issn | 2045-2322 |
| language | English |
| publishDate | 2025-07-01 |
| publisher | Nature Portfolio |
| record_format | Article |
| series | Scientific Reports |
| spelling | doaj-art-3c6819dcd0e64b31bf33bddfe487ca6f2025-08-20T03:04:29ZengNature PortfolioScientific Reports2045-23222025-07-0115111010.1038/s41598-025-12596-1A Finnish nationwide population-based study on the survival of patients with peripheral T-cell lymphomaTaina Reunamo0Ilja Kalashnikov1Kreetta Lahtela2Marjukka Pollari3Leevi Viisanen4Susanna Mannisto5Sirkku Jyrkkiö6Sirpa Leppä7Department of Oncology, Turku University Hospital and University of Turku, Wellbeing Services County of Southwest FinlandResearch Programs Unit, Faculty of Medicine, University of HelsinkiDepartment of Oncology, Helsinki University Hospital Comprehensive Cancer CentreResearch Programs Unit, Faculty of Medicine, University of HelsinkiResearch Programs Unit, Faculty of Medicine, University of HelsinkiResearch Programs Unit, Faculty of Medicine, University of HelsinkiDepartment of Oncology, Turku University Hospital and University of Turku, Wellbeing Services County of Southwest FinlandResearch Programs Unit, Faculty of Medicine, University of HelsinkiAbstract Peripheral T-cell lymphomas (PTCLs) represent a heterogeneous group of rare malignancies with poor survival; however, population-based long-term survival data remain limited. We conducted a nationwide study to estimate overall survival (OS) and relative survival (RS) among 915 patients diagnosed with PTCLs from 2002 − 2018 (57% males, median age 67 years) using the Finnish Cancer Registry. The most common subtypes included PTCL not otherwise specified (PTCL NOS; 37%), angioimmunoblastic T-cell lymphoma (AITL; 27%), and ALK-anaplastic large cell lymphoma (ALK-ALCL; 12%). Age > 60 years at diagnosis, advanced stage, and male sex were associated with poorer OS. Five-year OS and RS were better in patients with ALK + ALCL compared with PTCL NOS (5-year OS: 85% vs 30%). Patients with ALK- ALCL had a favorable 5-year OS compared to PTCL NOS (46% vs 30%), while those with enteropathy-associated T-cell lymphoma (EATL) demonstrated worse OS (15%). There was no improvement in RS from 2002 − 2012 to 2013 − 2018. OS was better in patients (excluding ALK + ALCL) receiving high-dose chemotherapy (HDCT) compared to those for whom HDCT was not planned (HR 0.61; 95% CI 0.47 − 0.80). We conclude that RS did not improve during the study period; however, consolidation with HDCT for eligible patients resulted in favorable survival.https://doi.org/10.1038/s41598-025-12596-1 |
| spellingShingle | Taina Reunamo Ilja Kalashnikov Kreetta Lahtela Marjukka Pollari Leevi Viisanen Susanna Mannisto Sirkku Jyrkkiö Sirpa Leppä A Finnish nationwide population-based study on the survival of patients with peripheral T-cell lymphoma Scientific Reports |
| title | A Finnish nationwide population-based study on the survival of patients with peripheral T-cell lymphoma |
| title_full | A Finnish nationwide population-based study on the survival of patients with peripheral T-cell lymphoma |
| title_fullStr | A Finnish nationwide population-based study on the survival of patients with peripheral T-cell lymphoma |
| title_full_unstemmed | A Finnish nationwide population-based study on the survival of patients with peripheral T-cell lymphoma |
| title_short | A Finnish nationwide population-based study on the survival of patients with peripheral T-cell lymphoma |
| title_sort | finnish nationwide population based study on the survival of patients with peripheral t cell lymphoma |
| url | https://doi.org/10.1038/s41598-025-12596-1 |
| work_keys_str_mv | AT tainareunamo afinnishnationwidepopulationbasedstudyonthesurvivalofpatientswithperipheraltcelllymphoma AT iljakalashnikov afinnishnationwidepopulationbasedstudyonthesurvivalofpatientswithperipheraltcelllymphoma AT kreettalahtela afinnishnationwidepopulationbasedstudyonthesurvivalofpatientswithperipheraltcelllymphoma AT marjukkapollari afinnishnationwidepopulationbasedstudyonthesurvivalofpatientswithperipheraltcelllymphoma AT leeviviisanen afinnishnationwidepopulationbasedstudyonthesurvivalofpatientswithperipheraltcelllymphoma AT susannamannisto afinnishnationwidepopulationbasedstudyonthesurvivalofpatientswithperipheraltcelllymphoma AT sirkkujyrkkio afinnishnationwidepopulationbasedstudyonthesurvivalofpatientswithperipheraltcelllymphoma AT sirpaleppa afinnishnationwidepopulationbasedstudyonthesurvivalofpatientswithperipheraltcelllymphoma AT tainareunamo finnishnationwidepopulationbasedstudyonthesurvivalofpatientswithperipheraltcelllymphoma AT iljakalashnikov finnishnationwidepopulationbasedstudyonthesurvivalofpatientswithperipheraltcelllymphoma AT kreettalahtela finnishnationwidepopulationbasedstudyonthesurvivalofpatientswithperipheraltcelllymphoma AT marjukkapollari finnishnationwidepopulationbasedstudyonthesurvivalofpatientswithperipheraltcelllymphoma AT leeviviisanen finnishnationwidepopulationbasedstudyonthesurvivalofpatientswithperipheraltcelllymphoma AT susannamannisto finnishnationwidepopulationbasedstudyonthesurvivalofpatientswithperipheraltcelllymphoma AT sirkkujyrkkio finnishnationwidepopulationbasedstudyonthesurvivalofpatientswithperipheraltcelllymphoma AT sirpaleppa finnishnationwidepopulationbasedstudyonthesurvivalofpatientswithperipheraltcelllymphoma |